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Abstract
The search for influencing factors and new pathways
in aseptic loosening of arthroplasties is a major focus
of recent studies. Analyses of polymorphisms of
genes revealed a correlation between a specific allele
variant and aseptic loosening. The BCL2 gene encod-
ing Bcl-2 with its BCL2 -938C>A polymorphism is a
crucial factor of cell cycle control and cell survival.
The CALCA -1786T>C polymorphism belongs to
the CALCA gene encoding alpha-Calcitonin Gene
Related Peptide (CGRP) and Calcitonin. Both proteins
are important in bone metabolism and capable to in-
fluence the process of aseptic loosening. To date, no
studies are reported for aseptic loosening with these
two single nucleotide polymorphisms (SNPs). In a ret-
rospective study we determined the distribution of the
BCL2-938C>A and the CALCA-1786T>C polymor-
phisms in 87 subjects with aseptic loosened hip
arthroplasties using RFLP and pyrosequencing analy-
sis. Genotype distribution with prognosis of the hip
arthroplasty showed neither an association with clini-
cal characteristics of the patients nor the implantation
technique. We were unable to detect any influence of
these polymorphisms on time to aseptic loosening.
INTRODUCTION
Aseptic loosening of total joint replacement is one of
the major reasons for long term failure of arthroplasty
(Silva and Sandell 2002). Various studies have been
performed to understand the mechanisms of aseptic
loosening. The local osteolysis surrounding the pros-
thesis is initiated by an aseptic inflammatory response
after incorporation of wear particles by macrophages.
Via cytokines macrophages stimulate the proliferation
and differentiation of precursor osteoclasts into ma-
ture osteoclasts and fibroblasts producing a benign lo-
cal granulomatous tissue. This process results in im-
plant instability requiring expensive revision surgery.
We have recently published two articles about the in-
fluence of apoptosis (Landgraeber, Toetsch et al.
2006; Landgraeber, von Knoch et al. 2008) and neu-
ropeptides (i.e. alpha - Calcitonin-Gene Related Pep-
tide (CGRP) (Wedemeyer, Neuerburg et al. 2007) in
aseptic loosening.
Firstly, apoptosis is an important process to regulate
homeostasis in tissue. The proliferation and apoptosis
in normal tissue is controlled by a variety of proteins
of the Bcl-2 family (Chao and Korsmeyer 1998) con-
sisting of different regulators which can block or accel-
erate the apoptosis (Kroemer 1997). The founding
member of this family, Bcl-2 itself, is an inhibitor of
apoptotic cell death and can act in both antiapoptotic
and antiproliferative manners (Cory and Adams 2002).
Recently we showed a slight reaction using Bcl-2 anti-
bodies in immunochemistry with macrophages and gi-
ant cells in granulomatous tissue in loosened arthro-
plasties and concluded that it is most likely that wear
debris induced apoptotic reactions (Landgraeber,
Toetsch et al. 2006). The BCL2 gene is located on
chromosome 18q21.3 (Seto, Jaeger et al. 1988; Young
and Korsmeyer 1993). It consists of three exons and
two promoters. These two promoters have distinct
functions. Activation of the promoter P2 decreases the
activity of the other promoter P1, therefore acting as a
negative regulatory element (Bredow, Juri et al. 2007).
Park et al. have identified a common single nucleotide
polymorphism (SNP, –938C>A (rs 2279115)) in the in-
hibitory P2 promoter of the BCL2 gene (Park, Kim et
al. 2004). N￼ckel et al. showed that this polymorphism
has functional properties and alters the promoter activ-
ity of P2 and inversely the activity of P1 (Nuckel, Frey
et al. 2007). Furthermore this SNP has been repeatedly
associated with different diseases (Bachmann, Otter-
bach et al. 2007; Chen, Hu et al. 2007).
Secondly, a possible influence of the nervous sys-
tem on particle induced osteolysis was shown by
Ahmed et al.. They found alpha-CGRP-immunoreac-
tive nerve fibres at the interface membrane of arthro-
plasty. Alpha-CGRP is a neurotransmitter produced by
the central and peripheral nervous system and can be
found in all tissues surrounding joints and close to the
epiphyseal plate, indicating that alpha-CGRP has a
function in bone remodelling (Irie, Hara-Irie et al.
2002). Our study group recently demonstrated the im-
pact on particle induced osteolysis in alpha-CGRP
knock-out mice (Wedemeyer, Neuerburg et al. 2007).
Therefore we focused on the CALCA gene (11p15.2-
p15.1), encoding both alpha-CGRP and Calcitonin.
Calcitonin is nearly exclusively produced by thyroid
cells (Jacobs, Goodman et al. 1981; Amara, Jonas et al.
1982; Rosenfeld, Mermod et al. 1983). This polypep-
tide consisting of 32 amino acids plays a role in calci-
um haemostasis by the inhibition of osteoclasts. How-
ever, its physiological function is not clarified in all de-
tails (Huebner, Schinke et al. 2006). The CALCA
gene consists of one promoter and six exons. CAL-
CA polymorphisms have been examined in many dif-
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venich, Xiang et al. 2001; Hink, Hokanson et al. 2003;
Goodman, Ferrell et al. 2005; Morita, Nakayama et al.
2007). Two common polymorphisms – CALCA -
1786T>C (rs3781719) and –1752C>G (rs1553005) –
in complete linkage are located in the promoter re-
gion. Goodman et al. showed a strong association of
these CALCA polymorphism with the risk of ovarian
cancer among some subgroups (Goodman, Ferrell et
al. 2005).
The aim of this study was to investigate the possi-
ble influence of the functional BCL2 (-938 C>A) and
CALCA (-1786T>C) polymorphisms on aseptic loos-
ening of total hip replacement.
MATERIALS AND METHODS
PATIENTS
Our collective consisted of 87 Caucasian patients of
German ancestry operated for aseptic loosening of
prosthetic hip joints at the Department of Or-
thopaedic Surgery (Medical Faculty, University of
Duisburg-Essen, Germany). For all patients strict in-
clusion and exclusion criteria were applied. Entry cri-
teria for this study were the clinical, radiological and
intra-surgical diagnosis of aseptic loosening after total
hip arthroplasty due to primary osteoarthritis. Exclu-
sion criteria were any deep infection or the suspicion
of implant infection, traumatic loosening, inflammato-
ry diseases or intake of immunosuppressant agents af-
ter total hip arthroplasty in the patient’s history. In 36
of 87 cases we performed a revision of the stem and
the cup, in 24 of 87 cases only the stem and in 27 cas-
es of 87 only the cup. The present study was per-
formed according to the Declaration of Helsinki and
approved by the local Ethics Committee of the Uni-
versity Hospital of Essen.
DETERMINATION OF BCL2 AND CALCA
GENOTYPES
DNA was extracted from routinely excised granuloma-
tous scared tissue surrounding the prosthesis. Isolation
of genomic DNA was performed using a commercial-
ly available kit (QIAamp, Qiagen, Hilden, Germany)
following the manufacturer’s instructions. Genotypes
of BCL2 -938C>A were determined by Slowdown
PCR and pyrosequencing as previously described
(Goodman, Ferrell et al. 2005; Nuckel, Frey et al.
2007). CALCA -1786T>C genotypes were deter-
mined by PCR using the following primers: forward
primer 5’-CGCTGGGCTGTTTCTCACAATAT-3’;
reverse primer, 5’-GTTAGACAGGAGTTCAATTAC
AGTTGGC -3’. After an initial denaturation at 94ﾰC,
38 cycles of DNA amplification were done using Taq
PCR Mastermix (Eppendorf, Hamburg, Germany) at
94ﾰC for 45 seconds, 62ﾰC for 40 seconds, and 72ﾰC
for 45 seconds. The 144 bp PCR products were digest-
ed using the restriction enzyme BsmAI (NEB, Ip-
swich, MA) and analyzed on a 2.5% agarose gel. Unre-
stricted products (144 bp) represent the TT genotype,
completely restricted products (115 + 29 bp) represent
the CC genotype.
STATISTICAL ANALYSIS
Kaplan-Meier plots and the log-rank test were used to
retrospectively evaluate the time to loosening, depen-
dent on BCL2 and CALCA genotypes, respectively.
Kruskal-Wallis test was used for comparison of
non-parametric variables where appropriate. Contin-
gency tables and Pearson’s χ2-test were used to
compare categorical variables using BCL2 and
CALCA genotypes as indicated. ANOVA was used
for comparison of continuous variables. The impact
of age, BMI, and BCL2 and CALCA genotypes as
prognostic factors for time to aseptic loosening were
analysed by univariate Cox regression models. Hazard
ratios (HR) and 95% confidence intervals (95% CI)
were calculated from these Cox regression models.
Control for deviation from the Hardy-Weinberg
equilibrium was conducted with the public domain
program Hardy-Weinberg equilibrium by J. Ott
(http://www.genemapping.cn/util.htm). Differences
were regarded significant at p < 0.05. Statistical analy-
sis was performed using SPSS 15.0 (SPSS, Chicago, IL,
USA) and GraphPad Prism 4.0 (GraphPad Software,
San Diego, CA, USA).
RESULTS
In our cohort genotype distributions of BCL2 -
938C>A (CC:22 CA:49 AA:16) as well as CALCA -
1786T>C (TT:42 TC:35 CC:10) were not significantly
different from Hardy–Weinberg equilibrium. Clinico-
pathological characteristics are shown in Tables 1 and
2. Age at the first implantation, age at the revision,
gender, body weight, body height, Body Mass Index,
Paprosky`s score (Paprosky, Bradford et al. 1994) (a
classification system in grades, based on preoperative
x-rays of the bone loss surrounding a loosened im-
plant), first cup with or without cement and first stem
with or without cement were not associated with
BCL2 and CALCA genotypes, respectively.
Neither time to aseptic loosening nor median time
to aseptic loosening showed a significant association
with BCL2 and CALCA genotypes (Fig. 1). Median
time to reimplantation due to aseptic loosening was
101 months (range 1-367) for BCL2 -938 CC ho-
mozygous patients, 86 months (range 5-384) for pa-
tients heterozygous for BCL2 -938 and 52 months
(range 0-344) for GG genotype carriers (p = 0.543).
Kaplan-Meier curve dependent on BCL2 -938 geno-
types showed no significant association (Fig. 1A, p =
0.985). Following Hazard Ratios (HR) and 95% Confi-
dence intervals (CI) were calculated for BCL2 -938
genotypes: CA vs. CC HR 0.982, 95%CI 0.59-1.63, p
= 0.945 and AA vs. CC HR 1.033, 95%CI 0.54-1.99, p
= 0.923. Median time to aseptic loosening for CAL-
CA -1786T>C genotypes was 69 months (range 2-
357) for CC genotype carriers, 57 months (range 1-
384) for heterozygous and 82.5 months (range 0-273)
for TT homozygous patients (p = 0.772). No associa-
tion was detectable in CALCA -1786 dependent Ka-
plan-Meier curve (Figure 1B, p = 0.378). Hazard Ra-
tios were 0.793, 95%CI 0.50-1.26, p = 0.323 for TC
vs. TT and HR 0.647, 95%CI 0.32-1.31, p = 0.224 for
CC vs. TT. Additionally performed subgroup analyses
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Table 1. Clinical characteristics and genotype distribution in patients with aseptic loosening.
BCL-2 genotype
All p-value
CC CA AA
n (%) 87 22 (25.28) 49 (56.32) 16 (18.4)
Age at implantation (y) 60.18 ﾱ 13.14 58.14 ﾱ 14.06 60.94 ﾱ 13.72 60.69 ﾱ 10.08 0.703
Age at replantation (y) 69.31 ﾱ 10.27 67.41 ﾱ 12.77 70.04 ﾱ 9.81 69.69 ﾱ 7.79 0.605
Gender
Female (%) 60 (68.97) 12 (20.0) 35 (58.33) 13 (21.66) 0.182
Male (%) 27 (31.03) 10 (37.04) 14 (51.86) 3 (0.11)
Weight (kg) 75.11 ﾱ 17.11 75.88 ﾱ 19.59 76.1 ﾱ 16.65 71.13 ﾱ 15.18 0.592
Height (cm) 166.80 ﾱ 8.35 168.09 ﾱ 6.91 166.77 ﾱ 9.13 165.13 ﾱ 7.95 0.563
BMI (kg/m_) 26.86 ﾱ 5.07 26.74 ﾱ 6.04 27.25 ﾱ 4.92 25.9 ﾱ 4.15 0.655
First cup with cement (n = 83)
no 34 (40.96) 6 (17.65) 19 (55.88) 9 (26.47) 0.280
yes 49 (59.04) 14 (28.57) 28 (57.14) 7 (14.29)
First stem with cement (n = 80)
no 30 (37.5) 4 (13.33) 19 (63.33) 7 (23.33) 0.147
yes 50 (62.5) 16 (32.0) 27 (54.0) 7 (14.0)
Acetabular defects (Paprosky) n = 60
I 6 (10) 3 (50.0) 2 (33.33) 1 (16.66) 0.479
II 23 (38.83) 5 (21.74) 12 (52.17) 3 (13.04)
III 31 (51.66) 7 (22.58) 17 (54.84) 7 (22.58)
Femoral defects (Paprosky) n = 52
1 4 (7.69) 4 (100) 0 0 0.377
2 23 (44.23) 5 (21.74) 14 (60.87) 4 (17.39)
3 25 (48.08) 8 (32.0) 12 (48.0) 5 (20.0)
Data are numbers with percentages given in brackets and numbers with standard deviation, respectively. Categorical variables
were analyzed by χ2 statistics. P values were calculated using ANOVA for continuous variables.
Table 2. Clinical characteristics and genotype distribution in patients with aseptic loosening.
CALCA genotype
All p-value
CC CT TT
n (%) 87 10 (11.49) 35 (40.22) 42 (48.3)
Age at implantation (y) 60.18 ﾱ 13.14 54.3 ﾱ 23.17 59.46 ﾱ 10.47 62.19 ﾱ 11.85 0.215
Age at replantation (y) 69.31 ﾱ 10.27 66.3 ﾱ 13.27 69.0 ﾱ 9.74 70.29 ﾱ 10.02 0.535
Gender
Female (%) 60 (68.97) 8 (13.33) 27 (45.0) 25 (41.66) 0.182
Male (%) 27 (31.03) 2 (7.41) 8 (29.63) 17 (62.96)
Weight (kg) 75.11 ﾱ 17.11 72.36 ﾱ 15.92 72.91 ﾱ 16.83 77.45 ﾱ 17.61 0.781
Height (cm) 166.80 ﾱ 8.35 164.5 ﾱ 8.17 166.00 ﾱ 8.31 167.9 ﾱ 8.45 0.828
BMI (kg/m_) 26.86 ﾱ 5.07 26.69 ﾱ 5.04 26.29 ﾱ 4.86 27.37 ﾱ 5.30 0.437
First cup with cement (n = 83)
no 34 (40.96) 2 (5.88) 17 (50.0) 15 (44.12) 0.171
yes 49 (59.04) 8 (16.33) 16 (32.65) 25 (51.02)
First stem with cement (n = 80)
no 30 (37.5) 2 (6.66) 13 (43.33) 15 (50.0) 0.510
yes 50 (62.5) 7 (14.0) 17 (34.0) 26 (52.0)
Acetabular defects (Paprosky) n = 60
I 6 (10) 1 (16.66) 2 (33.33) 3 (50.0) 0.880
II 23 (38.83) 2 (8.7) 13 (56.52) 8 (34.78)
III 31 (51.66) 5 (16.13) 11 (35.48) 15 (48.39)
Femoral defects (Paprosky) n = 52
1 4 (7.69) 0 2 (50.0) 2 (50.0) 0.723
2 23 (44.23) 4 (17.39) 9 (39.13) 10 (43.48)
3 25 (48.08) 2 (8.0) 10 (40.0) 13 (52.0)
Data are numbers with percentages given in brackets and numbers with standard deviation, respectively. Categorical variables
were analyzed by χ2 statistics. P values were calculated using ANOVA for continuous variables.
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years) and gender differences showed no significant
association with genotypes (Data not shown).
DISCUSSION
Despite multiple studies to understand and treat
aseptic loosening, it is still one of the major problems
of arthroplasty. The number of potential replace-
ments is limited due to continued loss of bone sub-
stance. In contrast to septic loosening or material fail-
ure no specific measures are available to reduce the in-
cidence of aseptic implant loosening until now. Several
studies aimed to determine risk factors to detect pa-
tients at higher risk who may benefit from prophylac-
tic regimens before implantation, e.g. weight reduc-
tion, or pharmacological prophylaxis after implanta-
tion. More precise prediction of the individual risk
would facilitate to make clinical decision. Unfortunate-
ly, clinical parameters for aseptic loosening have yield-
ed partly inconclusive results, e.g. age (Berry, Harmsen
et al. 2002; Flugsrud, Nordsletten et al. 2007). It is
commonly believed that genetic host factors can influ-
ence the incidence and course of aseptic loosening.
Recent in-vivo studies of our research group showed
the genetic influence on aseptic loosening in knock
out mice (Wedemeyer, Neuerburg et al. 2007). There-
fore, the aim of the present study was to investigate
whether a genetic host factor can be found in humans.
The common BCL2 -938 and CALCA -1786 poly-
morphisms in the genes BCL2 and CALCA may in-
fluence time to aseptic loosening in patients with hip
joint replacement and could be used as prediction for
time of loosening. Firstly, BCL2 was found in the key
cells of particle induced osteolysis (macrophages, lym-
phocytes) in loosened arthroplasties (Landgraeber,
Toetsch et al. 2006) and may have an impact in bone
metabolism.
Secondly, the CALCA gene is of great importance
for the bone metabolism obviously seen in the
phaenotype of increased bone formation rate in
CALCA knock out mice. Furthermore we could
show higher rates of particle induced osteolysis in al-
pha-CGRP knock out mice.
All in all, we could not find any significant correla-
tion between time and median time to aseptic loosen-
ing and BCL2 -938 as well as CALCA -1786 geno-
types. We were not able to compare the genotype dis-
tributions of BCL2 -938 and CALCA -1786 with a
population of patients with total hip replacement not
suffering from aseptic loosening. Therefore we explo-
ratively compared the genotype distributions with a
collective of healthy controls witch were comparable
with our cohort in age and gender distribution (Nuck-
el, Frey et al. 2007). Interestingly, BCL2 -938 geno-
types showed a significantly different distribution (CC:
21, CA 63, AA 36, p = 0.0416). The BCL2 -938CC
genotype was at highest risk for aseptic loosening,
Odds Ratio (OR) CC vs. AA 2.357, 95%CI 1.02-5.46,
p = 0.0434 with heterozygous at intermediate risk with
OR 1.750, 95%CI 0.87-3.52, p = 0.1138 for CA vs.
AA. Although it is too early for conclusions about this
association, the detected association would be in line
with functional data of this SNP. The A-allele of this
polymorphism is associated with increased Bcl-2 ex-
pression (Nuckel, Frey et al. 2007) causing less apop-
tosis around the implant which would explain the sig-
nificance for less aseptic loosing in patient homozy-
gous and heterozygous for the A-allele of the BCL2 -
938 SNP. Therefore, this result suggests the BCL2 -
938 SNP as an interesting candidate for further stud-
ies.
Unfortunately, statistic analysis did not show signifi-
cances for the CALCA SNP in contrast to our previ-
ous mammalian study with alpha CGRP knockout
mice (Buervenich, Xiang, et al. 2001). On the one hand,
this might be mainly due to the control collective and
the small number of patients in our study. A larger
more homogenous collective might show significant
changes and can detect effect from very low pene-
trance genes. Moreover, conclusions drawn from this
study may not be generalised to all patients undergo-
ing hip replacement - because genetic polymorphisms
often vary between ethnic groups of patients. On the
other hand, it has to be emphasized that the CALCA
SNP has shown some significant associations in other
studies, but - in contrast to the BCL2 SNP - its func-
tional properties have not been evaluated until now.
Caused by our retrospective collective we could not in-
fluence slight differences in physical parameters such
as implant design, quality of implantation and stress.
Aseptic loosening is a multifactorial process caused by
foreign body reaction, allergic reaction, particles, cell
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Fig. 1. Time to aseptic loosening based on Kaplan-Meier
curves. (A) Patients based on BCL2 -938 genotype. (B) Pa-
tients based on CALCA – 1786 genotype.
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ment, body weight, failure of implantation and im-
plant (Silva and Sandell 2002; Drees, Eckardt et al.
2007). As different types of arthroplasty show a dif-
ferent extent of osteolysis a genetic analysis should be
prospectively undertaken with the same implant type.
Asymptomatic patients with the same implant and im-
plantation technique would be a better collective for
comparison. Furthermore it can not be ruled out the
possibility that other, not yet identified, alterations in
genes involved in cell cycle, apoptosis, receptor ex-
pression, DNA replication and gene expression may
increase the risk of aseptic loosening after total hip re-
placement.
Therefore prospective, independent studies with
strict inclusion criteria have to be undertaken in the
future to rule out all factors uncorrelated to genetics.
Furthermore, the inclusion criteria for a prospective
study should aim at the bone quality. Although, pa-
tients with septic and traumatic loosening, rheuma-
tism, intake of immunosuppressants were excluded in
our study we did not measure the exact bone quality at
implantation and revision, e.g. osteomalacia, osteo-
porosis, sclerosis and osteopetrosis.
The genetic influence on humans in this multifacto-
rial process could be shown in this analysis.
Until now the outstanding number-one-reason for
particle induced osteolysis has not been found and will
possibly not be found in the genes either. Definitely,
further polymorphisms have to be analysed as a genet-
ic impact on aseptic loosening was obviously and sig-
nificantly shown in alpha-CGRP knock out mice in
our calvarian model. It bears the chance to analyse a
genetic impact on particle induced osteolysis.
All in all, this study combined with our results in
the mammalian model support the concept of a role
of BCL2 -938 genotypes in aseptic loosening. Further
independent and prospective replication studies are
necessary to confirm the general validity of our find-
ings, and deduced hypotheses and aim at the CALCA
-1786 polymorphism for a second time. Additionally,
other genes and genetic polymorphisms could play a
major role in the interaction of biomaterials and the
environment. Research in this field could lead to better
understanding of pathomechanisms and secondary
improve the results of arthroplasty.
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